Epic Sciences Inc. is a privately held diagnostics company that is developing highly sensitive tests to identify and molecularly characterize circulating tumor cells (CTCs) through a minimally invasive blood sample. We’ve developed a powerful rare-cell detection and characterization platform, which was founded on unique technology, exclusively licensed from The Scripps Research Institute. This unbiased and enrichment-free approach will empower the personalization and monitoring of cancer treatments.
Our partners include more than 37 pharmaceutical and biotechnology companies, major cancer centers, the National Cancer Institute (NCI) and the National Institutes of Health (NIH). These collaborations use the Epic Sciences platform to observationally monitor changes in the composition of CTCs during the course of study. Furthermore, our no cell left behind® technology can help match patients to the right therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point.
Our mission is to improve patient lives by enabling precision medicine with non-invasive tests that profile rare cells in cancer.
NEWS: Genomic Health and Epic Sciences Announce Strategic Collaboration to Deliver Novel AR-V7 Liquid Biopsy Test to Predict Treatment Response in Metastatic Prostate Cancer